Cardiovascular physiology

Marius Announces Ambulatory Blood Pressure Results Published in the Journal of Clinical Hypertension with their new testosterone medication KYZATREX™

Retrieved on: 
Friday, June 11, 2021

Effects of Oral Testosterone Undecanoate KYZATREX on Ambulatory Blood Pressure in Hypogonadal Men was published by William B.

Key Points: 
  • Effects of Oral Testosterone Undecanoate KYZATREX on Ambulatory Blood Pressure in Hypogonadal Men was published by William B.
  • The publication of these results marks a significant milestone in the field of testosterone therapy as ambulatory blood pressure monitoring (ABPM) is the most accurate means to detect small BP changes in clinical trials and practice.
  • commented, The changes in ambulatory BP were quite minimal in our study and of no clinical significance in normotensive men, a first in the testosterone space.
  • Shalin Shah, Co-CEO of Marius commented, We are extremely proud of the blood pressure data produced across all patient groups.

CVRx® Announces First Clinical Procedure with a New Ultrasound-Guided Implant Approach, the Latest Advancement in Barostim™ for the Treatment of Heart Failure Symptoms

Retrieved on: 
Thursday, June 10, 2021

The novel ultrasound-guided technique is the latest advancement of CVRxs Barostim Baroreflex Activation Therapy (BAT) to treat the symptoms of HF patients.

Key Points: 
  • The novel ultrasound-guided technique is the latest advancement of CVRxs Barostim Baroreflex Activation Therapy (BAT) to treat the symptoms of HF patients.
  • Commenting on the technology, Dr. Allred said, This new approach to treatment represents a potentially game-changing advancement in the way we manage patients with HF symptoms.
  • We are excited to participate in this study evaluating the ultrasound-guided approach as a new implant technique to deliver this therapy.
  • CVRx is dedicated to improving patient outcomes, quality of life, and overall cardiovascular health via novel baroreceptor neuromodulation therapies.

Lingering Supply-Demand Imbalance Continues to Drive Prices Even Higher, Latest HouseCanary Data Shows

Retrieved on: 
Thursday, June 10, 2021

HouseCanary, Inc. (HouseCanary), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between May 2020 and May 2021.

Key Points: 
  • HouseCanary, Inc. (HouseCanary), a leading provider of residential real estate data and home valuations, today released its latest Market Pulse report, covering 22 listing-derived metrics and comparing data between May 2020 and May 2021.
  • The Market Pulse is an ongoing review of proprietary data and insights from HouseCanarys nationwide platform.
  • The inventory deficit that developed in the wake of the COVID-19 pandemic continues to drive single-family home prices higher, leading to record levels of price growth across the United States.
  • As a result of these astronomical home prices and relatively stagnant mortgage rates, the number of people applying for mortgages has slowed recently.

Retia Medical Announces Bernd Saugel has Joined the Clinical Advisory Board

Retrieved on: 
Tuesday, June 1, 2021

VALHALLA, N.Y., June 01, 2021 (GLOBE NEWSWIRE) -- Retia Medical, an innovator in hemodynamic monitoring that helps clinicians guide care to prevent complications from high-risk surgeries such as heart attacks, strokes, and acute kidney injuries, today announced that Bernd Saugel, MD, EDIC joins other distinguished clinicians on Retia Medicals Clinical Advisory Board.

Key Points: 
  • VALHALLA, N.Y., June 01, 2021 (GLOBE NEWSWIRE) -- Retia Medical, an innovator in hemodynamic monitoring that helps clinicians guide care to prevent complications from high-risk surgeries such as heart attacks, strokes, and acute kidney injuries, today announced that Bernd Saugel, MD, EDIC joins other distinguished clinicians on Retia Medicals Clinical Advisory Board.
  • We are delighted to welcome Dr. Saugel to our Clinical Advisory Board, said Marc Zemel, S.M., M.B.A., co-founder and Chief Executive Officer of Retia Medical.
  • Retia Medicals Argos Cardiac Output Monitor, with its Multi-Beat Analysis (MBA) algorithm, eliminates a critical problem with older cardiac output technologies.
  • Retia Medical is proud to positively impact patient care in the U.S. and internationally as more hospitals continue to incorporate the Argos Cardiac Output Monitor into their standard of care.

One Drop Receives CE Mark, Launches Data-Driven Insights For People Managing High Blood Pressure

Retrieved on: 
Wednesday, May 26, 2021

As part of the One Drop Digital Membership , consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.

Key Points: 
  • As part of the One Drop Digital Membership , consumer and employer members worldwide can now receive in-app messages with blood pressure trends, behavioral reinforcements, and alerts for hypertensive crises.
  • ONE DROP RECEIVES CE MARK, LAUNCHES DATA-DRIVEN INSIGHTS FOR PEOPLE MANAGING HIGH BLOOD PRESSURE
    Often referred to as the "silent killer," high blood pressure affects one in three American adults and two-thirds of American adults living with diabetes [ 1 ].
  • Left untreated, high blood pressure can lead to heart disease, heart failure, and stroke [ 2 ], making early detection and daily blood pressure management critical for cardiometabolic health.
  • "As with most chronic conditions, blood pressure management requires deliberate action each day, but progress occurs over time.

Get your heart pumping and reap the benefits

Retrieved on: 
Wednesday, May 19, 2021

"\nTo strengthen your cardiovascular system, it is important to increase your heart rate for 20 to 60 minutes at your target heart rate each time you exercise.

Key Points: 
  • "\nTo strengthen your cardiovascular system, it is important to increase your heart rate for 20 to 60 minutes at your target heart rate each time you exercise.
  • Exercising at your target heart rate ensure your body is exerting enough energy to reap the benefits.
  • To accurately track how hard your body is working, calculate your target heart rate and track beats per a minute.
  • The key is to keep your heart rate steady and to exercise to your fitness level in order avoid injury.

Orchestra BioMed™ Announces Clinical Data Showing Significant and Sustained Reduction in Systolic Blood Pressure Out to Two Years with BackBeat Cardiac Neuromodulation Therapy™

Retrieved on: 
Monday, May 17, 2021

Of the 26 treatment patients, 25 completed 18 months of follow-up (one patient died of cancer) and 17 reached 24 months of therapy to date.

Key Points: 
  • Of the 26 treatment patients, 25 completed 18 months of follow-up (one patient died of cancer) and 17 reached 24 months of therapy to date.
  • Orchestra BioMed\xe2\x80\x99s CE Mark-approved Moderato\xc2\xae implantable pulse generator system delivers BackBeat CNT while also providing standard pacemaker functions.
  • BackBeat CNT mimics the effects of multi-drug hypertension therapy by targeting preload, afterload and sympathetic tone.
  • Orchestra BioMed was formed in 2018 by assembling a pipeline of multiple late-stage clinical product candidates originally developed by the Company\xe2\x80\x99s founding team.

Imbria Pharmaceuticals Presents Phase 1 and Preclinical Data of IMB-1018972 (IMB-101), an Investigational Cardiac Mitotrope, at the American College of Cardiology 70th Annual Scientific Session & Expo

Retrieved on: 
Monday, May 17, 2021

In a separate preclinical study, IMB-101 improved cardiac remodeling and function in a clinically relevant disease model of heart failure (murine permanent coronary artery ligation).

Key Points: 
  • In a separate preclinical study, IMB-101 improved cardiac remodeling and function in a clinically relevant disease model of heart failure (murine permanent coronary artery ligation).
  • The two studies were featured in presentations at The American College of Cardiology 70th Annual Scientific Session & Expo (ACC.21).\n\xe2\x80\x9cOur Phase 1 healthy volunteer study data add to the growing evidence that oral administration of IMB-101 is a well-tolerated metabolic agent,\xe2\x80\x9d said Anne Prener, M.D., Ph.D., President and CEO of Imbria Pharmaceuticals.
  • \xe2\x80\x9cIn our preclinical study, we found IMB-101 administered in a murine surgical model of post-myocardial infarction heart failure mice progressively improved left ventricular systolic function while reducing myocardial fibrosis.
  • The MAD part (n=12/cohort) used 50 and 150 mg IMB-101 or placebo twice per day for 14 days.

Global Ambulatory Blood Pressure Monitoring Systems Market (2021 to 2025) - Featuring Halma, Microlife and OMRON Among Others - ResearchAndMarkets.com

Retrieved on: 
Friday, May 14, 2021

b'The "Global Ambulatory Blood Pressure Monitoring Systems Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe publisher has been monitoring the ambulatory blood pressure monitoring systems market and it is poised to grow by $42.46 million during 2021-2025, progressing at a CAGR of almost 11% during the forecast period.\nThe report on the ambulatory blood pressure monitoring systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\nThe report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.

Key Points: 
  • b'The "Global Ambulatory Blood Pressure Monitoring Systems Market 2021-2025" report has been added to ResearchAndMarkets.com\'s offering.\nThe publisher has been monitoring the ambulatory blood pressure monitoring systems market and it is poised to grow by $42.46 million during 2021-2025, progressing at a CAGR of almost 11% during the forecast period.\nThe report on the ambulatory blood pressure monitoring systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.\nThe report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment.
  • The market is driven by the increasing incidence of hypertension coupled with the geriatric population and favorable reimbursement scenario.\nThe ambulatory blood pressure monitoring systems market analysis includes the product segment and geographic landscape.
  • This study identifies advanced technology support and improved monitoring techniques as one of the prime reasons driving the ambulatory blood pressure monitoring systems market growth during the next few years.\nBOSCH + SOHN GmbH u. Co. KG\n'

Daxor Corporation Announces 61% Increase in Q1 2021 Sales Revenue and Further Acquisitions of its BVA-100® Blood Volume Analyzer by Leading Medical Centers Throughout the U.S.

Retrieved on: 
Thursday, May 13, 2021

b'NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis.

Key Points: 
  • b'NEW YORK, NY, May 13, 2021 (GLOBE NEWSWIRE) -- Daxor Corporation (NYSE MKT: DXR), the global leader in blood volume measurement technology, today announced a Q1 2021 increase in revenue of 61% in its operating division on a year-over-year basis.
  • "We expect that we will have access to over 70% of our client hospitals by the end of Q2 2021.
  • We developed and market the BVA-100\xc2\xae (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms.
  • Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.\n'